NCT05499377

Brief Summary

This project examines the influence of flavor availability on switching to an MRTP known as IQOS, part of the Heated Tobacco Product (HTP) class, among menthol smokers using clinical lab and naturalistic evaluations of abuse liability. Results will help federal regulators predict the public health impact on menthol cigarette smokers of policies restricting access to menthol-flavored HTPs.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
33

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 10, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 12, 2022

Completed
4 months until next milestone

Study Start

First participant enrolled

November 28, 2022

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 22, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 22, 2023

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

January 31, 2025

Completed
Last Updated

January 31, 2025

Status Verified

January 1, 2025

Enrollment Period

10 months

First QC Date

August 10, 2022

Results QC Date

August 26, 2024

Last Update Submit

January 27, 2025

Conditions

Keywords

Heated Tobacco ProductsFlavorAbuse LiabilityTobaccoCigarettesMentholExperimental Tobacco MarketplaceNicotine DeliveryPuff TopographyEcological Momentary AssessmentModified Risk Tobacco ProductIQOSHeated Tobacco Products Flavors

Outcome Measures

Primary Outcomes (3)

  • Percent Change in Average Daily Cigarette Use Per Day From Baseline

    Average number of cigarettes consumed per day, collected via daily text/email survey, averaged overconsumption for Tues-Thurs of each week. Outcome will compare the percent change in cigarette consumption from the baseline week (OB menthol cigarette use) to the intervention week (IQOS use) between the two study arms.

    Week 1 (baseline) to Week 2 (intervention)

  • Percent Increase in Demand as the Subject is Willing to Substitute From Cigarettes to HTPs Using the Experimental Tobacco Marketplace Task

    Participants will complete the Experimental Tobacco Marketplace Task - which asks participants to allocate a hypothetical budget across a large menu of products. In each session, cigarette prices increased ($0.12, $0.25, $0.50, $1.00. and $2.00 per cigarette) while prices for alternative products remained fixed. Across three ETM sessions, either all products, all products except little cigars and cigarillos (LCCs), or all products except ENDS (JUUL e-cigarettes) were available. Linear regression is performed on individual participant data using log-transformed cigarette price to determine demand and substitution. Reported demand for tobacco products is used to determine substitution between IQOS and cigarettes. Purchasing decisions are not reinforced. Outcome will compare the cross-price elasticity (CPE) of IQOS with respect to menthol cigarettes among those with access to IQOS-menthol and IQOS-Tobacco (IQOS-M group) compared to those with access to IQOS-tobacco only (IQOS-T group).

    Week 2, Friday Clinical Lab visit

  • Plasma Nicotine Delivery

    Change in the plasma nicotine levels from before to after a standardized 10-puff (30-sec interpuff interval) bout with IQOS in the participant's assigned flavor. Outcome will compare the average plasma nicotine boost (the change in plasma nicotine levels from before to after the standardized puffing bout) across two study arms as well as compared to own-brand menthol cigarettes.

    Week 2, Friday Clinical Lab visit (10 puff bout period)

Secondary Outcomes (3)

  • Cigarette Craving Suppression Questionnaire

    Week 2, Friday Clinical Lab Visit (10 puff bout period)

  • Puff Topography (Puff Duration)

    Week 2, Friday Clinical Lab visit (10 puff bout period)

  • Average Daily IQOS Usage

    Week 2 (intervention week), Tuesday-Thursday

Study Arms (2)

Tobacco-Flavored IQOS

ACTIVE COMPARATOR

Tobacco - where menthol smokers will only have access to tobacco-flavored HeatSticks to use in the IQOS 2.4 Tobacco Heating System

Device: Tobacco product administration and assessment

Menthol-Flavored IQOS

EXPERIMENTAL

Menthol - where menthol smokers will only have access to menthol-flavored HeatSticks to use in the IQOS 2.4 Tobacco Heating System

Device: Tobacco product administration and assessment

Interventions

Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 2 HTP flavor conditions (tobacco-flavored HeatSticks or Fresh Menthol-flavored HeatSticks), with equal probability and provided with a supply of their condition specific HTP and asked to use it in place of their usual menthol cigarettes for the next week. Participants use their own brand menthol cigarettes and assigned HTP both at home (naturalistic use) and in the clinical laboratory (two visits/week).

Menthol-Flavored IQOSTobacco-Flavored IQOS

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy adults (aged 21 and older)
  • Daily menthol cigarette smokers
  • Exhaled Carbon Monoxide (CO) reading of \> 5 PPM at in-person screening (to confirm smoking status)
  • A 'positive' cotinine cassette result to verify nicotine use at the in-person screening.
  • Participants must be willing to provide informed consent and abstain from nicotine/tobacco for ≥8 hours prior to each lab session.
  • Participants must have access to a computer/smartphone and be willing to receive and respond to daily surveys
  • Able to read and write in English

You may not qualify if:

  • Daily use of any tobacco products other than cigarettes
  • Self-reported history of chronic medical or psychiatric conditions
  • Women will be excluded if they test positive for pregnancy (by urinalysis) or self-report breastfeeding.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Virginia Commonwealth University

Richmond, Virginia, 23298, United States

Location

Related Publications (1)

  • White AM, Imran R, Gaitan N, Bickel WK, Perera RA, Cobb CO, Eissenberg TE, Barnes AJ. A Pilot RCT Exploring Heated Tobacco Product Substitution for Menthol Cigarettes. Am J Prev Med. 2025 Nov;69(5):108029. doi: 10.1016/j.amepre.2025.108029. Epub 2025 Aug 5.

MeSH Terms

Conditions

Tobacco Use

Interventions

Physical Examination

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and ProceduresDiagnosis

Results Point of Contact

Title
Augustus Whiet
Organization
Virginia Commonwealth University

Study Officials

  • Andrew J Barnes, PhD

    Virginia Commonwealth University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 10, 2022

First Posted

August 12, 2022

Study Start

November 28, 2022

Primary Completion

September 22, 2023

Study Completion

September 22, 2023

Last Updated

January 31, 2025

Results First Posted

January 31, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Locations